Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostatic Disease Clear all
Terminated Phase 2 Interventional Results available

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

NCT04176497
View directory record Official record
Conditions
Prostate Cancer
Interventions
68Ga-HBED-CC-PSMA
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 16, 2026, 10:44 AM EDT
Terminated No phase listed Observational

Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583

NCT00898833
View directory record Official record
Conditions
Prostate Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02737332
View directory record Official record
Conditions
Prostate Cancer
Interventions
Zytiga® (Abiraterone Acetate), SoluMatrix™ (Abiraterone Acetate)
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Laguna Hills, California • Los Angeles, California • San Bernardino, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 16, 2026, 10:44 AM EDT
Not yet recruiting Phase 1 Interventional

Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer

NCT07756593
View directory record Official record
Conditions
Prostate Cancer, Metastatic Prostate Cancer
Interventions
Sipuleucel-T, N803
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy

NCT01656304
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
bevacizumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

NCT00448409
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
TroVax, GM-CSF
Biological · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 16, 2026, 10:44 AM EDT
Terminated Phase 2 Interventional

Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

NCT01340599
View directory record Official record
Conditions
Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
defined green tea catechin extract, placebo, immunohistochemistry staining method, immunoenzyme technique, questionnaire administration, therapeutic conventional surgery, high performance liquid chromatography, mass spectrometry
Dietary Supplement · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Not applicable Interventional Results available

MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer

NCT03664193
View directory record Official record
Conditions
Prostate Cancer
Interventions
SIBRT
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer

NCT00244309
View directory record Official record
Conditions
Prostate Cancer
Interventions
tamsulosin and/or dutasteride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Sep 16, 2026, 10:44 AM EDT
Recruiting Phase 1 Interventional

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

NCT04729114
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Interventions
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
24
States / cities
Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of PET/MRI Tracer to Further Understanding of Prostate Cancer Development

NCT02106416
View directory record Official record
Conditions
Prostate Cancer, Bladder Cancer
Interventions
PET/MRI
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 16, 2026, 10:44 AM EDT
Not listed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

NCT00003633
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, estramustine phosphate sodium, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 16, 2026, 10:44 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Hispanic Adapted and Culturally Relevant Exercising Together

NCT06018311
View directory record Official record
Conditions
Neoplasms, Prostate Cancer, Exercise, Caregiver Burden, Cancer Survivors
Interventions
Exercising together
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer

NCT03373006
View directory record Official record
Conditions
Prostate Cancer
Interventions
Axumin PET/CT
Drug
Lead sponsor
HALO Diagnostics
Industry
Eligibility
45 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Indian Wells, California
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 16, 2026, 10:44 AM EDT
Recruiting No phase listed Observational

Circulating Tumor DNA in High Risk Localized Prostate Cancer

NCT07222436
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

NCT03572387
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Neoplasms, Prostate Cancer
Interventions
5-Azacitidine, all trans retinoic acid, Lupron
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer

NCT00137436
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Prednisone, SU011248
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
24
States / cities
Harvey, Illinois • Tinley Park, Illinois • Hobart, Indiana + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2011 · Synced Sep 16, 2026, 10:44 AM EDT
Recruiting Phase 1 Interventional

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

NCT07517198
View directory record Official record
Conditions
Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC)
Interventions
EXS74539
Drug
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Los Angeles, California • Fort Worth, Texas • West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Completed No phase listed Observational

Urology Database to Evaluate Clinical Information and Improve Patient Care.

NCT00376298
View directory record Official record
Conditions
Incontinence, Prostate Cancer, Interstitial Cystitis, Urinary Retention, Pelvic Organ Prolapse
Interventions
Not listed
Lead sponsor
Kenneth Peters, MD
Other
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 16, 2026, 10:44 AM EDT
Terminated Phase 1Phase 2 Interventional

64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

NCT05633160
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
64Cu-SAR-BBN, 67Cu-SAR-BBN
Drug
Lead sponsor
Clarity Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Stanford, California • Miami, Florida • Grand Rapids, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 16, 2026, 10:44 AM EDT
Terminated Phase 2 Interventional Results available

Abiraterone Acetate Trial in African American Prostate Cancer Patients

NCT01735396
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 16, 2026, 10:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

NCT05652686
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Interventions
Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab, Lurbinectedin, Irinotecan (drug), Topotecan
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

NCT01485861
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone, Apitolisib, Ipatasertib, Placebo, Prednisone, Prednisolone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
12
States / cities
Scottsdale, Arizona • San Francisco, California • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Not applicable Interventional

Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection

NCT00303654
View directory record Official record
Conditions
Bladder Cancer
Interventions
biopsy, therapeutic conventional surgery
Procedure
Lead sponsor
Roei Medical Technologies Ltd.
Industry
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 16, 2026, 10:44 AM EDT